- Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy
- Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue
- In in the list of top 20 companies- BMS secured the top position with total revenue of $28B from oncology segment in 2020- followed by Roche and Merck with $26B & $15B
Oncology Segment Revenue: $0.23B
Founding Year: 1984
Market Cap: $11.03B
Total Employees: 22,739
Headquarter: Hyderabad- India
Stock Exchange: NSE
Dr.Reddy is an Indian Pharmaceutical company that is mainly involved in developing a wide range of generic formulations and proprietary products. The company focuses on multiple therapeutic areas including oncology- cardiovascular- dermatology- gastrointestinal- diabetology- pain management- and nephrology. In September 2020- Dr. Reddy’s Laboratories launched Faslodex (fulvestrant) injection which is used to treat metastatic breast cancer. The company generated a sale of $0.23B from its oncology segment in 2020.
Oncology Segment Revenue: $0.30B
Founding Year: 2010
Market Cap: $32.58B
Total Employees: 5,100
Headquarter: Beijing- China
Stock Exchange: HKG
BeiGene is a global biotechnology company that focuses mainly on developing medicines for cancer treatment. In June 2020- BeiGene reported EMA’s acceptance of its marketing authorization application for Brukinsa (zanubrutinib) for the treatment of patients with Waldenstrom’s Macroglobulinemia. In 2020- BeiGene’s key drug- Brukinsa generated total sales of $0.04B and the company generated total revenue of $0.30B from the oncology segment.
Oncology Segment Revenue: $0.39B
Founding Year: 2005
Market Cap: $49.86B
Total Employees: 16,033
Headquarter: Tokyo- Japan
Stock Exchange: TYO
Daiichi Sankyo is a global pharmaceutical company that focuses on developing novel therapies in therapeutic areas including oncology and rare diseases. In May 2020- Daiichi Sankyo launched Enhertu in Japan for patients with metastatic breast cancer. In 2020- the company’s key drug- Trastuzumab deruxtecan (Enhertu) generated total sales of $0.39B.
Oncology Segment Revenue: $0.51B
Founding Year: 2000
Market Cap: $100.88B
Total employees: 94,066
Headquarter: Brentford- United Kingdom
Stock Exchange: LON
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that focuses on developing therapies in areas including oncology- respiratory- and immuno-inflammation. In August 2020- FDA approved GSK’s Blenrep for the treatment of patients with relapsed or refractory multiple myeloma. With its two approved drugs- Zezula and Blenrep- GSK generated total revenue of $0.51B from its oncology segment in 2020.
Oncology Segment Revenue: $0.67B
Founding Year: 1987
Market Cap: $89.26B
Total Employees: 13,600
Headquarter: California- United States
Stock Exchange: NASDAQ
Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing medicines in areas including HIV/AIDS- oncology- liver diseases- and hematology- inflammatory and respiratory. In October 2020- Gilead Sciences acquired Immunomedics. Gilead’s oncology drug- Yescarta recorded total sales of $0.56B in 2020. The company generated total revenue of $0.67B from its oncology segment in 2020.
Oncology Segment Revenue: $0.97B
Founding Year: 1973
Market Cap: $126.55B
Total Employees: 99,412
Headquarter: Paris- France
Stock Exchange: EPA
Sanofi is a French multinational pharmaceutical company that focuses on developing novel therapies for oncology- cardiovascular- neurology- immunology- and inflammation. In June 2020- European Commission approved Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma. Sanofi’s leading oncology drug- Jevtana recorded sales of $0.65B last year. In 2020- Sanofi generated total revenue of $0.97B from its oncology segment.
Oncology Segment Revenue: $1.68B
Founding Year: 1863
Market cap: $55.01B
Total Employees: 99,538
Headquarter: Leverkusen- Germany
Stock Exchange: ETR
Bayer is a German multinational pharmaceutical company with a focus on cancer- cardiovascular- and kidney diseases. In March 2020- Nubeqa received EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer. Bayer’s leading drug- Nexavar recorded total sales of $0.78B last year. In 2020- Bayer generated total revenue of $1.68B from its oncology segment.
Oncology Segment Revenue: $2.06B
Founding Year: 1991
Market Cap: $16.50B
Total Employees: 1,773
Headquarter: Delaware- United States
Stock Exchange: NASDAQ
Incyte is an American multinational pharmaceutical company that focuses on multiple therapeutic areas including oncology- inflammation and autoimmunity. In May 2020- the US FDA approved Tabrecta (capmatinib) for the treatment of patients with metastatic NSCLC with METex14. The leading oncology drug of the company- Jakafi recorded total sales of $1.93B while the total revenue of the company is $2.06B from its oncology segment.
Oncology Segment Revenue: $3.76B
Founding Year: 1781
Market Cap: $54.41B
Total Employees: 47,099
Headquarter: Tokyo- Japan
Stock Exchange: TYO
Takeda is a Japanese multinational pharmaceutical company that develops innovative therapies in areas including oncology- rare diseases- and gastroenterology. In May 2020- the US FDA approved Takeda Alunbrig as a 1L treatment for patients diagnosed with a rare and serious form of lung cancer. Last year- the company generated total revenue of $3.76B from its oncology segment.
Oncology Segment Revenue: $4.47B
Founded Year: 2005
Market cap: $32.57B
Total Employees: 15,455
Headquarter: Tokyo- Japan
Stock Exchange: TYO
Astellas Pharma is a Japanese multinational pharmaceutical company that focuses on developing novel therapies for therapeutic areas including oncology- nephrology- urology- and transplantation. In 2020- Astellas acquired Audentes Therapeutics- and its product- Xtandi received Xtandi’s approval in NMPA for the treatment of non-mCRPC. Xtandi (lead drug) contributes 90% of the total oncology segment i.e $4.14B whereas Astellas generated total revenue of $4.47B from the oncology segment.
Oncology Segment Revenue: $5.31B
Founding Year: 1876
Market Cap: $243.78B
Total Employees: 34,960
Headquarter: Indiana- United States
Stock Exchange: NYSE
Eli Lilly is an American pharmaceutical company that deals in oncology- endocrinology- neurodegenerative diseases- immunology- pain- and migraine. In 2020- Selpercatinib (Retevmo) was granted accelerated approval by the FDA for thyroid and lung cancer. Alimta- the leading candidate of the company recorded total sales of $2.33B whereas the total revenue oncology segment is $5.31B in 2020
Oncology Segment Revenue: $6.65B
Founding Year: 2013
Market Cap: $195.03B
Total Employees: 47,000
Headquarter: Illinois- United States
Stock Exchange: NYSE
Abbvie is an American pharmaceutical company that focuses on developing novel products for therapeutic areas including oncology- immunology- dermatology- and virology. In 2020- Venclexta received FDA approval for AML and Imbruvica recorded total sales of $5.31B. Last year- Abbvie generated total revenue of $6.65B from its oncology segment.
Oncology Segment Revenue: $8.32B
Founding Year: 1980
Market Cap: $125.42B
Total Employees: 24,300
Headquarter: California- United States
Stock Exchange: NASDAQ
Amgen is an American biopharmaceutical company that is working on multiple therapeutic areas including oncology- neurology- immunology- nephrology- and inflammation. In December 2020- FDA approved Riabni- a biosimilar to Rituxan- for the treatment of adult patients with NHL & CLL. Amgen’s key drug- Xgeva recorded total sales of $1.89B while the company generated total revenue of $8.32B from its oncology segment.
Oncology Segment Revenue: $10.85B
Founding Year: 1999
Market Cap: $181.52B
Total Employees: 76,100
Headquarter: Cambridge- United Kingdom
Stock Exchange: NASDAQ
AstraZeneca is a multinational pharmaceutical and biotechnology company that focuses on a portfolio of products in areas including oncology- cardiovascular- gastrointestinal- infection- respiratory- and inflammation. In September 2020- AZ’sImfinzi was approved in the EU for 1L treatment of adults with ES-SCLC. Last year- Tagrisso recorded total sales of $4.32B while the company’s total revenue is $10.85B from its oncology segment.
Oncology Segment Revenue: $10.86B
Founding Year: 1849
Market Cap: $262.11B
Total Employees: 78,500
Headquarter: New York- United States
Stock Exchange: NYSE
Pfizer is an American multinational pharmaceutical and biotechnology company that develops novel medicines and vaccines for therapeutic areas including oncology- immunology- cardiology- endocrinology and neurology. In June 2020- the EU approved Bavencio as a treatment for patients with LA or metastatic urothelial carcinoma. Pfizer’s leading drug- Ibrance recorded 50% of the total sales of the company in the oncology segment i.e. $5.39B.
Oncology Segment Revenue: $12.36B
Founding Year: 1887
Market Cap: $452.52B
Total Employees: 134,500
Headquarter: New Jersey- United States
Stock Exchange: NYSE
Johnson and Johnson is an American multinational pharmaceutical company that has a product portfolio of multiple therapeutic areas including CV- oncology- immunology- and endocrinology. In its oncology segment- J&J focuses on core diseases including prostate cancer and multiple myeloma. The company’s leading drug- Darzalex recorded total sales of $4.19B whereas the total revenue is $12.36B in the oncology segment.
Oncology Segment Revenue: $14.71B
Founding Year: 1996
Market Cap: $222.98B
Total Employees: 105,794
Headquarter: Basel- Switzerland
Stock Exchange: SWX
Novartis is a Swiss multinational pharmaceutical company that works in multiple disease areas including oncology- hepatology- immunology- dermatology- musculoskeletal diseases- neuroscience- and ophthalmology. In 2020- Novartis generated total revenue of $14.71B from its oncology segment.
Oncology Segment Revenue: $15.83B
Founding Year: 1891
Market Cap: $190.76B
Total Employees: 74,000
Headquarter: New Jersey- United States
Stock Exchange: NYSE
Merck is an American multinational pharmaceutical company focused on developing innovative medicines in areas including oncology- infectious diseases- respiratory and immunology. In 2020- FDA approved Merck Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer. Keytruda recorded total sales of $14.38B whereas the total revenue of the company is $15.83B in its oncology segment.
Oncology Segment Revenue: $26.37B
Founding Year: 1896
Market Cap: $380.16B
Total Employees: 101,465
Headquarter: Basel- Switzerland
Stock Exchange: SWX
Roche is a Swiss multinational pharmaceutical company focused on developing products in areas including oncology- immunology- and ophthalmology- cardiovascular and respiratory. In December 2020- EC approved Roche Phesgo for people with HER2- breast cancer. Roche’s Avastin recorded total sales of $5.64B whereas the company generated total revenue of $26.37B from its oncology segment.
Oncology Segment Revenue: $28.14B
Founding Year: 1887
Market Cap: $144.86B
Total Employees: 30,250
Headquarter: New York- United States
Stock Exchange: NYSE
BMS is a global biopharmaceutical company focused on developing innovative products in oncology- immunology- and hematology- cardiovascular. In November 2020- BMS received EC’s approval for Opdivo + Yervoy with two cycles of CT for 1L treatment of mNSCLC. BMS Revlimid recorded total sales of $12.10B while the company generated total revenue of $28.14B from its oncology segment.
Source: Company annual reports- SEC filings- press releases- and company websites
https://googleads.g.doubleclick.net/pagead/ads?gdpr=0&us_privacy=1—&gpp_sid=-1&client=ca-pub-9265584400550148&output=html&h=280&adk=1951076301&adf=3907382762&pi=t.aa~a.2937610975~i.933~rp.4&w=804&abgtt=6&fwrn=4&fwrnh=100&lmt=1743742574&num_ads=1&rafmt=1&armr=3&sem=mc&pwprc=9424952870&ad_type=text_image&format=804×280&url=https%3A%2F%2Fpharmashots.com%2F7538%2Ftop-20-oncology-companies-based-on-2020-oncology-segment-revenue&fwr=0&pra=3&rh=200&rw=804&rpe=1&resp_fmts=3&wgl=1&fa=27&uach=WyJXaW5kb3dzIiwiMTkuMC4wIiwieDg2IiwiIiwiMTM1LjAuNzA0OS40MSIsbnVsbCwwLG51bGwsIjY0IixbWyJHb29nbGUgQ2hyb21lIiwiMTM1LjAuNzA0OS40MSJdLFsiTm90LUEuQnJhbmQiLCI4LjAuMC4wIl0sWyJDaHJvbWl1bSIsIjEzNS4wLjcwNDkuNDEiXV0sMF0.&dt=1743742554353&bpp=4&bdt=1111&idt=4&shv=r20250403&mjsv=m202504010101&ptt=9&saldr=aa&abxe=1&cookie=ID%3D93ad4f2cb6db9efe%3AT%3D1743660961%3ART%3D1743742418%3AS%3DALNI_MZS_QdB5YthXTydRGmTP0mS3bTEiQ&gpic=UID%3D0000108832690403%3AT%3D1743660961%3ART%3D1743742418%3AS%3DALNI_MbJwxow-ZjN6Qdm72xJ08gekgt-kQ&eo_id_str=ID%3D5c6e1dd85f610f93%3AT%3D1743660961%3ART%3D1743742418%3AS%3DAA-AfjbEovGr5ivBpgWMB887rJqm&prev_fmts=0x0%2C804x280&nras=3&correlator=4111087809249&frm=20&pv=1&u_tz=330&u_his=50&u_h=864&u_w=1536&u_ah=816&u_aw=1536&u_cd=24&u_sd=1.25&dmc=8&adx=358&ady=10183&biw=1521&bih=730&scr_x=0&scr_y=7322&eid=95355973%2C95355975%2C95332590%2C31089209%2C95356787%2C95356929&oid=2&psts=AOrYGsmIiefKpew7M0Cads43gxKXUhWCVkkzYWCHDtmjLCNryBl9BLN0FW8MQeXmshNsAwb1Qbt8vWj2dnGWxJ9vPAByvOLj&pvsid=2988565738514670&tmod=2099213525&uas=3&nvt=1&ref=https%3A%2F%2Fpharmashots.com%2Fcategory%2Ftop20&fc=1408&brdim=0%2C0%2C0%2C0%2C1536%2C0%2C1536%2C816%2C1536%2C730&vis=1&rsz=%7C%7Cs%7C&abl=NS&fu=128&bc=31&bz=1&td=1&tdf=2&psd=W251bGwsbnVsbCxudWxsLDNd&nt=1&ifi=2&uci=a!2&btvi=2&fsb=1&dtd=20097
Market Cap source: Google finance (as of 09th September 2021)
All revenues are reported in USD.
Related Post: Top 20 Oncology Companies by Total Products of 2019
